(Q52579719)

3 May 2018

title

Simvastatin inhibits TNFalpha-induced invasion of human cardiac myofibroblasts via both MMP-9-dependent and -independent mechanisms. (English)

1 reference

3 May 2018

1 reference

1

1 reference

3 May 2018

Ian C Wood

8

1 reference

3 May 2018

Karen E Porter

10

Karen E Porter

0 references

Kersten Hall

3

Kersten T Hall

1 reference

3 May 2018

4

Philip Warburton

1 reference

3 May 2018

Stacey Galloway

5

Stacey Galloway

1 reference

3 May 2018

Lynne Midgley

6

Lynne Midgley

1 reference

3 May 2018

author name string

Parvinder K Aley

2

1 reference

3 May 2018

David J O'Regan

7

1 reference

3 May 2018

Stephen G Ball

9

1 reference

3 May 2018

publication date

18 May 2007

1 reference

3 May 2018

Journal of Molecular and Cellular Cardiology

published in

1 reference

3 May 2018

volume

43

1 reference

3 May 2018

issue

2

1 reference

3 May 2018

page(s)

168-176

1 reference

3 May 2018

Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough?

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.05.006

The cardiac fibroblast: therapeutic target in myocardial remodeling and failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.05.006

Fibrosis in hypertensive heart disease: focus on cardiac fibroblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.05.006

Structural and functional characterisation of cardiac fibroblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.05.006

Molecular mechanisms of myocardial remodeling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.05.006

Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.05.006

Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.05.006

Tumor Necrosis Factor Soluble Receptors in Patients With Various Degrees of Congestive Heart Failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.05.006

Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the studies of left ventricular dysfunction (SOLVD)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.05.006

Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.05.006

Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.05.006

Tumor necrosis factor-alpha provokes a hypertrophic growth response in adult cardiac myocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.05.006

Tumor necrosis factor-alpha at acute myocardial infarction in rats and effects on cardiac fibroblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.05.006

Tumor necrosis factor alpha induces human atrial myofibroblast proliferation, invasion and MMP-9 secretion: inhibition by simvastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.05.006

Statins in the 21st century: end of the simple story?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.05.006

Pleiotropic effects of HMG-CoA reductase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.05.006

Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.05.006

Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.05.006

Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.05.006

Impact of hydroxymethylglutaryl coenzyme a reductase inhibition on left ventricular remodeling after myocardial infarction: an experimental serial cardiac magnetic resonance imaging study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.05.006

Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.05.006

Statin use in heart failure: a cause for concern?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.05.006

Statins in the treatment of chronic heart failure: biological and clinical considerations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.05.006

Effects of statin therapy on the development and progression of heart failure: mechanisms and clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.05.006

Chronic beta2-adrenergic receptor stimulation increases proliferation of human cardiac fibroblasts via an autocrine mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.05.006

Simvastatin reduces human atrial myofibroblast proliferation independently of cholesterol lowering via inhibition of RhoA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.05.006

Selective gene silencing of either MMP-2 or MMP-9 inhibits invasion of human saphenous vein smooth muscle cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.05.006

Simvastatin inhibits human saphenous vein neointima formation via inhibition of smooth muscle cell proliferation and migration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.05.006

The mechanism of angiotensin II-induced extracellular signal-regulated kinase-1/2 activation is independent of angiotensin AT(1A) receptor internalisation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.05.006

Lovastatin inhibits phenylephrine-induced ERK activation and growth of cardiac.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.05.006

Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.05.006

Matrix metalloproteinase-9 is necessary for the regulation of smooth muscle cell replication and migration after arterial injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.05.006

Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.05.006

Rho kinases in cardiovascular physiology and pathophysiology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.05.006

Distinct involvement of cdc42 and RhoA GTPases in actin organization and cell shape in untransformed and Dbl oncogene transformed NIH3T3 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.05.006

Screening for cell migration inhibitors via automated microscopy reveals a Rho-kinase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.05.006

HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.05.006

Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.05.006

Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA/ROCK pathway and reducing MMP-9 mRNA levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.05.006

Hypoxia reduces the output of matrix metalloproteinase-9 (MMP-9) in monocytes by inhibiting its secretion and elevating membranal association

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.05.006

Coordination of cell signaling, chromatin remodeling, histone modifications, and regulator recruitment in human matrix metalloproteinase 9 gene transcription

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.05.006

Novel regulation of type IV collagenase (matrix metalloproteinase-9 and -2) activities by transforming growth factor-beta1 in human prostate cancer cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.05.006

Nitric oxide increases the decay of matrix metalloproteinase 9 mRNA by inhibiting the expression of mRNA-stabilizing factor HuR.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.05.006

Role of nucleolin in posttranscriptional control of MMP-9 expression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.05.006

10.1016/J.YJMCC.2007.05.006

7 January 2021

Identifiers

DOI

1 reference

3 May 2018

PubMed ID

17560598

1 reference

3 May 2018